Poseida
Roche Acquires Poseida Therapeutics for Up to $1.5 Billion, Expanding Off-the-Shelf CAR-T Capabilities
Roche, Poseida Therapeutics, CAR-T therapy, off-the-shelf cell therapies, allogeneic cell therapy, biotech acquisition
Roche Acquires CAR-T Partner Poseida Therapeutics for $1 Billion Upfront
Roche, Poseida Therapeutics, CAR-T, cell therapy, acquisition, biotechnology, pharmaceuticals
Poseida Therapeutics Advances Non-Viral Gene Editing Therapy for Hereditary Angioedema
Poseida Therapeutics, non-viral gene editing, hereditary angioedema (HAE), P-KLKB1-101, Cas-CLOVER, liver-directed gene therapy